Ori Biotech

Introducing IRO®, the new standard in CGT manufacturing technology. 🎉 Manufacturing remains a critical barrier to scaling cell and gene therapies – making it difficult to meet the patient need, and limiting the clinical and commercial impact of this new class of therapies. That’s why we developed IRO®. IRO® combines an efficient and flexible platform with a scalable, digital solution to industrialize precision medicine manufacturing – delivering a seamless transition from R&D into the clinic, and from clinical scale to commercial scale. By empowering scientists with tools that help accelerate product development and Automate Better Biology, we are working to help enable widespread patient access and scale the impact of life-changing cell and gene therapies. Thank you to everyone who attended our launch at ISCT today. It's an incredibly exciting moment to finally unveil our work over the past 5-years – we are very grateful to the Ori team and our partners for helping us achieve this milestone. Read our full press release: https://lnkd.in/eT3B3MSf Schedule a hands on demo to see how IRO® could work for you: https://lnkd.in/eXEXEGZZ #ISCT2024 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #Biotechnology

In 2022, Dr. Flores, a family physician with a lifelong commitment to helping others, was diagnosed with Stage 3 multiple myeloma. The road ahead looked uncertain: standard treatments weren’t working, and his condition worsened. While stage 3 is often considered terminal, Dr. Flores was not deterred and began CAR-T cell therapy at City of Hope. Despite some challenges along the way, Dr Flores' treatment was a success – living proof of the transformative potential of CAR-T therapy. Thank you to City of Hope for sharing this remarkable journey ➡️ https://lnkd.in/ecnF3UDv #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Through our collaboration with Charles River Laboratories, we are setting a new standard in CAR-T manufacturing... Recently, our CEO, Jason C. Foster and Matthew Hewitt, Vice President, CTO Manufacturing Business Division, at Charles River Laboratories, spoke to BioProcess International about our ongoing collaboration and joint commitment to scale CGT manufacturing to enable widespread patient access. They discussed how IRO® enhanced biological performance compared to a legacy manufacturing technology, methods to scale CGT production and future collaboration plans. "The IRO platform is designed to help address manufacturing bottlenecks that result in patient waitlists for manufacturing slots that put critically ill patients at risk. The collaboration with CRL helps refine and optimize the IRO platform to ensure it accelerates the development and delivery of therapies." – Jason C. Foster Read more about our collaboration at BioProcess International ➡️ https://lnkd.in/ecnJmryM #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact

🧬 CRISPR could help improve the success of CAR-T cell therapy Research by Saad Sirop Kenderiana, co-leader of Cancer Immunology and Immunotherapy at Mayo Clinic's Comprehensive Cancer Center, analyzed pre-infusion CAR-T cells from patients treated with CAR-T cell therapy. They then compared patients who achieved remission, with those who didn’t. They found that T-cell exhaustion contributes significantly to patient relapse, with a significant link between exhaustion and elevated levels of the interleukin-4 (IL-4) protein – which regulates inflammation and immunity – in both human and mouse models. ✂️ Using CRISPR gene-editing as “molecular scissors” the team knocked out the overabundance of the IL-4 protein in dysfunctional CAR-T cells, leading to a significant improvement in the anti-tumor effects. While this research finding is in its early stages, it is encouraging to see further developments in our understanding of T-cells and efforts to improve the efficacy of CAR-T therapies. Read the full paper ➡️ https://lnkd.in/e9vxywJD #CellTherapy #GeneTherapy #Biotechnology #ManufacturingBrighterFutures #PatientAccess

🔬 Our CEO Jason C. Foster will be attending J.P. Morgan Healthcare Conference 2025 in San Francisco. Want to schedule a meeting with Jason? Connect with him to learn more about IRO® and how we're helping to scale the impact of cell and gene therapies. 🔍 Learn more about IRO ➡️ https://lnkd.in/evCqHZnB #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact #JPM2025

🔬 Could enhancing glucose uptake in CAR-T therapies make them more potent? A recent study published in Nature Portfolio has demonstrated that overexpression of the glucose transporter, GLUT1, in CAR-T cells boosts their metabolism and improves anti-tumor response. These engineered cells demonstrated a reduction in cell exhaustion and greater persistence in fighting tumors with higher levels of differentiation, which has been linked to more robust immune responses. These cells also showed good tumor control in both in vitro and in vivo models. While still in its early stages, research like this highlights the growing momentum of scientific development into CAR-T therapy. This strategy could help improve CAR-T therapies in patients who do not initially respond well to treatment, making these incredible therapies more accessible to more patients. Read more in Nature ➡️ https://lnkd.in/eaYYUvJw #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🧬 At 76, Michael Hreha became the 200th patient at Rutgers Cancer Institute and RWJBarnabas Health to receive CAR-T therapy – a major milestone for New Jersey’s only NCI-designated Comprehensive Cancer Center. After being diagnosed with non-Hodgkin's lymphoma in 2019, his cancer eventually became resistant to treatment. That’s when Michael’s medical team introduced him to CAR-T. Thankfully, the treatment was successful. “I am incredibly grateful for the opportunity to receive CAR-T cell therapy close to home at Rutgers Cancer Institute. This treatment has given me a chance to fight back against my cancer and spend more time with my two sons and four grandchildren," said Michael. 🧫 Michael’s journey with CAR-T therapy highlights the life-changing potential of advanced therapies and the urgent need to make these treatments accessible to every patient who could benefit. Thank you to Rutgers Cancer Institute and RWJBarnabas Health for sharing this remarkable milestone ➡️ https://lnkd.in/gE-DhuWd #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

🦾 At this year's Cell & Gene Meeting on the Mesa, a key spotlight was firmly on early engagement with automation and the increasing emphasis on scalability in therapy development. However, automation isn’t just about streamlining processes; successful implementation requires overcoming bottlenecks that could hinder scalability. As Jason C. Foster, CEO of Ori Biotech, said in our panel: “You address the bottleneck. If you do that successfully, other unit operations will become bottlenecks upstream and downstream. You address those as appropriate to get whatever your desired throughput of the system is." We want to say a huge thank you to everyone who attended our panel and to the insightful speakers who joined Jason C. Foster on stage: 🔹 Julie G. Allickson, PhD, Director of Advanced Biotherapeutics, Mayo Clinic 🔹 Bruce Thompson, CEO, Kincell Bio 🔹 Matthew Hewitt, Vice President, CTO Manufacturing Business Division at Charles River Laboratories 🔹 Andrew Snowden, Vice President, Technical Officer Cell and Gene Therapy and Biologics at Johnson & Johnson Another highlight for the whole team was the fireside chat with former FDA commissioner Scott Gottlieb, where he spoke to his excitement for the use of cell and gene therapies in therapeutic areas of high unmet need, such as autoimmune diseases. And finally, Mesa marks the third conference this year where we've delivered live demos of our IRO® platform. It was fantastic to share in the excitement and engagement from the CGT community. If you didn't get the chance to see IRO® in action, reach out to schedule an in-person demonstration at our Philidelphia and London labs. Get in touch ➡️ https://lnkd.in/eEKch-4Z #AutomateBetterBiology #ManufacturingBrighterFutures #CellTherapy #GeneTherapy

⌛ Rethinking constraints in CGT manufacturing In the latest episode of the Ori Spotlight Podcast, Ori Biotech CEO Jason C. Foster chats with Director at Stand Back To Grow, Michael Krajewski, to unpack the Theory of Constraints concept and how this applies to cell therapy manufacturing. Michael explains how identifying the real bottleneck in a manufacturing workflow – whether it's the supply of materials or process timing – can shape more efficient, scalable workflows. Adding how navigating non-negotiable limitations, such as the cost of travel between each stage in the supply and manufacturing chain, can make the journey from lab to clinic more efficient, and make these high-impact therapies are more accessible to patients. 🎧 Listen on Spotify: https://lnkd.in/eRps2mMw 📺 Watch on YouTube: https://lnkd.in/eygYVHg2 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

"Charles River’s work with Ori is part of a larger commitment to improve and scale advanced therapies through the adoption of cutting-edge closed and automated platforms to meet the growing patient demand for life-saving therapies. The test of Ori’s new IRO platform using head-to-head process transfer runs shows promising results and provides therapeutic developers another option for manufacturing and helps to address the manufacturing bottleneck challenge.” - Matthew Hewitt, Vice President, CTO Manufacturing Business Division at Charles River Laboratories We recently presented new data from our ongoing collaboration with Charles River Laboratories, where Jason C. Foster highlighted IRO®’s ability to reduce cost of goods by up to 50% and cut production time by up to 25%. When compared to a legacy manufacturing technology, IRO not only delivered higher CAR+ cell yields in less time, but also streamlined workflows and enhanced biological performance – all of which were demonstrated live at our 'Experience IRO' event in Boston. By Automating Better Biology™, the IRO platform empowers therapy developers to scale their impact with efficient, standardized manufacturing processes. A huge thank you to the team at Charles River and to everyone who joined us in Boston. If you missed out, don’t worry – schedule your 1:1 demo to see IRO in action ➡️ https://lnkd.in/eXEXEGZZ Read more about our collaboration ➡️ https://lnkd.in/e5gT-zXz #IRO #TheNewStandard #AutomateBetterBiology #AccelerateProductDevelopment #ScaleYourImpact